<DOC>
	<DOCNO>NCT00326456</DOCNO>
	<brief_summary>The purpose study compare effectiveness ( progression free survival ) experimental combination carboplatin + liposomal doxorubicin standard combination carboplatin + paclitaxel first line treatment patient ovarian cancer . Secondary objective evaluate overall survival , quality life , objective response rate , toxicity .</brief_summary>
	<brief_title>MITO-2 : A Study Comparing 2 Chemotherapy Regimens ( Carboplatin/Liposomal Doxorubicin v Carboplatin/Paclitaxel ) Patients With Ovarian Cancer</brief_title>
	<detailed_description>Ovarian cancer second frequent deadly gynaecologic cancer . The high mortality rate due late diagnosis malignancy often develop without symptom , well limited result treatment disease . Patients may respond well initially chemotherapy , vast majority patient experience progression disease . The poor long term result standard treatment available today first-line chemotherapy ovarian cancer make research new , beneficial treatment strategy necessary . The proven efficacy liposomal doxorubicin second line treatment , first drug show significant benefit term survival , possibility easily combine full dos normal use carboplatin , encourage test effectiveness combination carboplatin liposomal doxorubicin first line treatment . Patients enrol study randomly assign one two treatment group : · Standard therapy consist 6 cycle chemotherapy : - carboplatin AUC 5 give intravenously day 1 every 3 week AND - paclitaxel 175 mg/m2 give intravenously day 1 every 3 week OR · Experimental therapy consist 6 cycle chemotherapy : - carboplatin AUC 5 give intravenously day 1 every 3 week AND - liposomal doxorubicin 30 mg/m2 give intravenously day 1 every 3 week</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Cytologic / histologic diagnosis stage IcIV ovarian cancer Indication chemotherapy treatment Age 75 year less Life expectancy least 3 month Previous concomitant malignant neoplasia ( include basocellular spinocellular skin carcinoma insitu carcinoma uterine cervix , provide adequately treat ) Performance status ( ECOG ) &gt; 2 Previous chemotherapy treatment Heart disease ( heart failure , myocardial heart attack within 6 month prior randomization , atrioventricular block degree , serious arrhythmia ) Leukocytes &lt; 4000/mm3 , neutrophil &lt; 2000/mm3 , platelet &lt; 100000/mm3 Impaired renal function ( creatinine &gt; 1.25 time upper normal limit ) liver function ( SGOT SGPT &gt; 1.25 time upper normal limit ) Present suspect hemorrhagic syndrome Uncooperative and/or unreliable patient Patient 's inability access center Refusal inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>first-line</keyword>
</DOC>